A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer-Reference-Cited by-同舟云学术

A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer

Published:2016-01-06 Issue:320 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Whitley Melodi Javid¹²,Cardona Diana M.³,Lazarides Alexander L.⁴,Spasojevic Ivan⁵⁶,Ferrer Jorge M.⁷,Cahill Joan⁸,Lee Chang-Lung⁸,Snuderl Matija⁹,Blazer Dan G.¹⁰,Hwang E. Shelley¹⁰,Greenup Rachel A.¹⁰,Mosca Paul J.¹⁰,Mito Jeffrey K.¹²,Cuneo Kyle C.⁸,Larrier Nicole A.⁸,O’Reilly Erin K.¹¹,Riedel Richard F.⁵,Eward William C.¹²,Strasfeld David B.⁷,Fukumura Dai⁹,Jain Rakesh K.⁹,Lee W. David⁷,Griffith Linda G.¹³,Bawendi Moungi G.¹⁴,Kirsch David G.¹⁸,Brigman Brian E.¹²

Affiliation:

1. Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA.

2. Medical Science Training Program, Duke University Medical Center, Durham, NC 27710, USA.

3. Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

4. School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

5. Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

6. PK/PD Core Laboratory, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.

7. Lumicell Inc., Wellesley, MA 02481, USA.

8. Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

9. Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

10. Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

11. Duke Translational Medicine Institute, Regulatory Affairs Group, Duke University Medical Center, NC 27710, USA.

12. Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC 27710, USA.

13. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

14. Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

Abstract

A first-in-human phase 1 clinical trial of the PEGylated protease-activated fluorescent probe, LUM015, enables tumor imaging at a safe and tolerable dose in humans.

Funder

American Society of Clinical Oncology Advanced Clinical Research Award

NIH

National Cancer Institute Small Business Innovation Research

National Center for Advancing Translational Science

Duke Comprehensive Cancer Center Support

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference40 articles.

1. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.